HIV Prevention Research & Development Investments

In its 17th annual report, the Resource Tracking for HIV Prevention Research & Development Working Group (“Working Group”) documents research and development spending for the calendar year 2020 and analyzes funding trends spanning twenty years.

US$ 0 B
Funding for HIV Prevention Research & Development in 2020

The most up-to-date and comprehensive field-wide estimates for HIV prevention and R&D globally.

The Working Group’s 2020 analysis builds on the US$19 billion in funding tracked between 2000 and 2019 and underscores the importance of continued innovation in HIV prevention to bring a lasting end to the HIV/AIDS pandemic.

The biomedical HIV prevention options tracked include preventive AIDS vaccines, microbicides, prevention of vertical transmission (PMTCT), pre-exposure prophylaxis (PrEP), treatment as prevention (TasP), voluntary medical male circumcision (VMMC) and female condoms.

Funding At a Glance

What are the historic and current trends for investment in HIV prevention R&D?

For Year:
0
US$ Million
icon
Preventative vaccines
0
US$ Million
icon
Microbicides
0
US$ Million
icon
Prevention of vertical transmission
0
US$ Million
icon
Pre-exposure prophylaxis
0
US$ Million
icon
Treatment as prevention
0
US$ Million
icon
Voluntary medical male circumcision
0
US$ Million
icon
Female Condoms
For Year:
0
US$ Million
icon
Multilateral Public Sector
0
US$ Million
icon
Europe - Public Sector
0
US$ Million
icon
US Public Sector
0
US$ Million
icon
Other Public Sector
0
US$ Million
icon
Wellcome Trust
0
US$ Million
icon
Bill & Melinda Gates Foundation
0
US$ Million
icon
Other Philanthropic
0
US$ Million
icon
Other Commercial

View past reports and resources.